BZL 101

Drug Profile

BZL 101

Alternative Names: Bezielle; BZL-101

Latest Information Update: 20 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bionovo
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants; Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Pancreatic cancer

Most Recent Events

  • 12 Mar 2012 No development reported - Preclinical for Pancreatic cancer in USA (PO)
  • 06 Feb 2012 Bionovo plans a phase II trial for Breast cancer in USA (NCT00907959)
  • 02 Nov 2010 Bionovo receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for controlled-release BZL 101 development in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top